ONLINE SUPPLEMENTARY CONTENT

Table SI - *Characteristics of the first two apheresis procedures for the total No.=41 patients*

Patient	Daratumumab	Vascular access	CD34+ count at 1st harvest	TBV processed during the 1st harvest	CD34+ $\times 10^6$/kg collected at 1st harvest	CD34+ count at 2nd harvest	TBV processed during the 2nd harvest	CD34+ $\times 10^6$/kg collected at 2nd harvest	Tot No. of aphereses	Plerixafor
#1	Y	Peripheral	3.35	3	9.184	N/A	N/A	N/A	1	Y
#2	Y	Peripheral	54.00	3	8.628	N/A	N/A	N/A	1	N
#3	Y	Peripheral	63.29	3	6.900	N/A	N/A	N/A	1	N
#4	Y	Central	74.44	3	6.367	N/A	N/A	N/A	1	N
#5	Y	Peripheral	17.21	3	1.680	32.93	3	3.610	2	Y
#6	Y	Peripheral	26.12	3	1.941	12.48	3	1.026	4	N
#7	Y	Peripheral	11.85	3	1.728	14.38	3	1.457	4	Y
#8	Y	Peripheral	43.00	3	3.808	48.00	3	4.136	2	N
#9	Y	Peripheral	39.15	3	3.235	39.81	3	3.826	2	N
#10	Y	Peripheral	65.90	3	5.468	N/A	N/A	N/A	1	N
#11	Y	Peripheral	20.00	3	2.699	26.00	3	3.867	2	Y
#12	Y	Central	39.10	3	5.290	55.90	1	1.240	2	N
#13	Y	Peripheral	56.94	3	5.474	22.79	1.5	3.181	2	N
#14	Y	Peripheral	52.09	3	4.279	33.19	3	4.669	2	N
#15	Y	Central	37.19	3	3.771	23.81	3	2.801	2	N
#16	Y	Peripheral	42.12	3	4.151	42.70	2.5	2.635	2	N
#17	Y	Peripheral	35.23	3	3.160	65.75	2.5	4.936	2	N
#18	Y	Peripheral	41.04	3	4.434	94.57	1.5	5.737	2	N
#19	Y	Peripheral	26.25	3	2.889	21.25	3	2.388	2	N
#20	Y	Peripheral	18.81	3	1.722	16.16	3	1.336	4	N
#21	N	Peripheral	139.86	2,5	16.846	N/A	N/A	N/A	1	N
#22	N	Peripheral	145.00	2	7.693	N/A	N/A	N/A	1	N
#23	N	Peripheral	101.12	2,5	9.107	N/A	N/A	N/A	1	N
#24	N	Peripheral	180.00	2	14.201	N/A	N/A	N/A	1	N
#25	N	Peripheral	52.79	3	6.432	N/A	N/A	N/A	1	N
#26	N	Peripheral	84.53	3	7.358	N/A	N/A	N/A	1	N
#27	N	Central	121.54	2,5	10.960	N/A	N/A	N/A	1	N
#28	N	Peripheral	64.21	3	6.872	N/A	N/A	N/A	1	N
#29	N	Peripheral	69.50	3	8.635	N/A	N/A	N/A	1	N
#30	N	Peripheral	161.75	1,5	8.109	N/A	N/A	N/A	1	N
#31	N	Peripheral	75.82	3	8.302	N/A	N/A	N/A	1	N
#32	N	Central	76.90	3	8.247	N/A	N/A	N/A	1	N
#33	N	Peripheral	34.04	3	6.080	N/A	N/A	N/A	1	N
#34	N	Peripheral	18.89	3	1.631	9.40	3	0.954	2	N
#35	N	Peripheral	54.73	3	4.460	40.60	3	3.406	2	N
#36	N	Peripheral	44.73	3	5.300	N/A	N/A	N/A	1	Y
#37	N	Peripheral	15.70	3	1.712	10.92	3	1.027	2	N
#38	N	Peripheral	63.62	3	5.262	N/A	N/A	N/A	1	N
#39	N	Peripheral	40.18	3	5.051	48.58	3	2.837	2	N
#40	N	Peripheral	55.05	3	3.823	67.50	2.5	3.920	2	N
#41	N	Central	53.88	3	5.301	N/A	N/A	N/A	1	N

N: no; Y: yes; N/A: not applicable.



Figure S1 - Induction therapy, radiotherapy and platelets number
A) Number of patients who did or did not undergo radiotherapy before CD34+ mobilization in the two induction therapy groups: daratumumab (blue) and non-daratumumab (red). **B**) Number of patients who had less than or more than 170.000/mmc platelets in the two induction therapy groups: daratumumab (blue) and non-daratumumab (red).



Figure S2 - Induction therapy and clinical response
Number of daratumumab-treated (red) and non-daratumumab treated patients (blue) who had achieved complete response (CR) or very good partial response (VGPR) at the time of CD34+ mobilization as opposed to patients who were reported to have achieved only a partial response (PR).



Figure S3 - Radiotherapy, platelets number and number of apheresis
Number of patients who did or did not undergo radiotherapy before CD34+ mobilization and needed to undergo one (blue) or more than one (red) apheresis sessions in order to reach the set CD34+ target
Number of patients who had less than or more than 170.000/mmc platelets and number of apheresis needed to reach the set CD34+ target: one (blue) and more than one (red).



Figure S4 - Clinical response, number of apheresis and pre-apheresis CD34+ count
Number of patients who had to undergo one (blue) or more than one (red) apheresis sessions divided into two groups based on the achieved response at time of mobilization (i.e., complete response [CR] or very good partial response [VGPR] and partial response [PR]).
Pre-apheresis CD34+ count in patients who had achieved a CR or VGPR as opposed to patients inPR.